Founding Cohort 2026, 9 spots remaining · 50% off Founders Rate For Life →
Authoritize.ai

Industries

GLP-1 and weight-loss marketing that holds up to the FTC

Compounded semaglutide and tirzepatide put weight-loss clinics in the overlap of FDA drug rules, brand trademarks, and the FTC’s weight-loss claim standards. Authoritize builds owned, physician-signed content that ranks for the searches patients actually run, without the shortcuts regulators are watching.

Where GLP-1 marketing gets clinics in trouble

Three pressures stack here. Brand names like Wegovy, Ozempic, and Zepbound cannot be used as if they describe a compounded product. Compounded semaglutide and tirzepatide can only be marketed under the conditions that actually permit compounding, which shift with the drug-shortage list. And the FTC’s weight-loss guidance treats certain claims, such as guaranteed pound counts, works-for-everyone, or results without diet or exercise, as deceptive on their face. Our GLP-1 enforcement guide walks the patterns, and the Atlas catalogs the real actions.

Honest weight-loss copy outperforms hype

Patients have seen the hype and learned to discount it, so the honest page usually wins. Explain how the medication works, give realistic ranges with the context that makes them true, attribute brand and compounded products correctly, cover candidacy and risk plainly, and let a licensed physician stand behind the clinical statements. That page earns the click and survives a regulator reading it.

What Authoritize builds for weight-loss clinics

Owned articles and authority pages that answer what prospective patients search about GLP-1 options, cost, candidacy, and what to expect, screened against FDA and FTC guidelines inside the pipeline, and signed by your supervising physician as the reviewer of record. It is the same content engine described on our compliant content page, tuned to the weight-loss vertical. You can pressure-test any existing page right now in the free Claim Checker.

Frequently asked questions

How do you market GLP-1 weight loss compliantly?

GLP-1 marketing sits in the overlap of FDA drug rules, brand trademarks, and the FTC’s weight-loss claim standards, so the copy has to clear all three. That means accurate mechanism, realistic outcomes with context, correct brand attribution, and no shortcuts the FTC has already flagged as deceptive. Authoritize builds owned, physician-signed content that ranks for the searches patients run and stays inside those lines. The free Claim Checker runs the screen on copy you already have.

What gets a weight-loss or GLP-1 clinic an FTC or FDA letter?

A few recurring things: misusing brand names like Wegovy, Ozempic, or Zepbound for a compounded product, marketing compounded semaglutide or tirzepatide outside the conditions that actually permit compounding, and making the outcome claims the FTC treats as facially deceptive, such as guaranteed pound counts, works-for-everyone, or no diet or exercise required. Before-and-after and testimonial content without substantiation adds to it.

Can weight-loss copy be honest and still convert?

Yes, and honest usually converts better. Patients have seen the hype and discount it. Describe how the medication works, give realistic ranges with context, attribute brand and compounded products correctly, cover candidacy and risk, and let a licensed physician stand behind the clinical claims. Straight answers earn the click and survive a regulator reading them.

Does Authoritize replace our physician’s review?

No. Authoritize screens content against documented enforcement patterns and drafts it to be defensible, but your supervising physician is the reviewer of record and the final gate on every clinical claim. The screen informs that review, it never substitutes for it.